0.43
0.43 (-8.13%)
As of Oct 24, 2023
Biocept Inc [BIOC]
Source:
Company Overview
Biocept Inc is a molecular oncology diagnostics company that develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF.
| Country | United States |
| Headquarters | san diego, california |
| Phone Number | 858-320-8200 |
| Industry | services |
| CEO | Samuel D. Riccitelli |
| Website | www.biocept.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0.6 |
| Operating Profit | $-6.1 |
| Net Income | $-3.6 |
| Net Cash | $-6.3 |
Profit Ratios
| Gross Margin | $-2 |
| Operating Margin | -1,038 |
| Profit as % of Revenues | -332.9% |
| Profit as % of Assets | -13.7% |
| Profit as % of Stockholder Equity | -1,252.1% |
Management Effectiveness
| Return on Equity | -1,252.1% |
| Return on Assets | -16.4% |
| Turnover Ratio | 0% |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $22.1 |
| Total Liabilities | $21.8 |
| Operating Cash Flow | $-9.3 |
| Investing Cash Flow | $-0.1 |
| Financing Cash Flow | $3.1 |
